A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. METHODS: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. RESULTS: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft-allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died. CONCLUSIONS: Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.138–140”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [139]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationGooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Research works printed but not linked: 1
- Sullivan KM, 1991, Semin Hematol, 28, 250
Cited by
Items 401–500 of 503
Wei, Y. (2015) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma
Bruno, B., Lia, G., Bonifazi, F., & Giaccone, L. (2021) · Hemato · doi:10.3390/hemato2010005 · Cited by 1
“The first study which showed superior results with the auto-allo tandem approach was reported by the Italian group [25,26].”
ResultSelf-citationMyeloma and Secondary Involvement of the Kidney in Dysproteinemias
Sanders, P. W. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50041-1 · Cited by 1
High-Dose Therapy in Multiple Myeloma
Harousseau, J. (2007) · Translational medicine series · doi:10.3109/9781420045116.010 · Cited by 1
Kako, S. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03631-w · Cited by 1
“On the other hand, evidence regarding allogeneic transplantation for MM is limited [32, 33], especially after the advent of novel drugs, such as proteasome inhibitors (PIs) [34], immunomodulatory drugs (IMiDs) [35], and monoclonal antibodies [36].”
Current status and future directions in the treatment of multiple myeloma
Hou, J., & Wang, M. L. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200710010-00001 · Cited by 1
Tricot, G. J. K., Zangari, M., Sorasio, R., & Bruno, B. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_14
“Though GvHD was associated with disease response in the majority of clinical trials, it is encouraging that more recent studies employing nonmyeloablative conditionings did not correlate disease response and its duration with the development of chronic GvHD (151,152).”
MethodResultSelf-citationThe Role of Allogeneic Bone Marrow Transplant in Cancer Treatment
Tomás, J. F., & Giralt, S. (2009) · Springer eBooks · doi:10.1007/978-1-84882-019-7_15
“Two large comparative trials have demonstrated a potential benefit for patients who underwent aR IC allograft as consolidation of an autologous SCT for primary therapy of myeloma [ 15 ,37].”
BackgroundMohty, M. (2007) · ONCOLOGIE · doi:10.1007/s10269-007-0761-7
“Même s’il n’existe pas d’études randomisées comparant les différents types de CIR, le conditionnement incluant une faible dose de TBI seule, est probablement associé à la toxicité la moins importante [3].”
BackgroundPidala, J., & Anasetti, C. (2011) · Wiley eBooks · doi:10.1002/9781444394016.ch23
Population-based studies on familiality and prognosis in patients with monoclonal gammopathies
Kristinsson, S. Y. (2009) · Figshare · Cited by 1
Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications
Gutman, J. A., Heimfeld, S., & Deeg, H. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_57
Immunobiology and Immunotherapy of Multiple Myeloma
Dhodapkar, M. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_11
Harnessing Allogeneic Immunity for Anti-myeloma Response
Bellucci, R., & Alyea, E. P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5260-7_5
“54 months) with a TRM of only 11% [ 46 ] .”
Autologous Stem Cell Transplantation in the Management of Multiple Myeloma
Gertz, M. A., & Reeder, C. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_10
Allogeneic transplantation in multiple myeloma
Majolino, I., & Severino, A. (2009) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842009000800011
ASH 2010 meeting report—Top 10 abstracts in hematopoietic stem cell transplantation
Frey, N. V., & Porter, D. (2011) · American Journal of Hematology · doi:10.1002/ajh.22022
“More importantly, unlike a very similar large study from Italy [7], the BMT CTN trial did not show a benefit out to 3 years for the auto/allo recipients compared to auto/auto recipients.”
ResultInfluentialLocalized graft-versus-host disease of the skin provoked by radiotherapy
van de Donk, N. W. C. J., van Dijk, M. R., & Lokhorst, H. M. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.044
Fujikawa, K., Nakaseko, C., Cho, R., Abe, D., Oda, K., Tanaka, H., Ohwada, C., Ozawa, S., Takeuchi, M., Sakaida, E., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705843
Management of Myeloma: An Italian Perspective
Bruno, B., Gay, F., Boccadoro, M., & Palumbo, A. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.026
Self-citationTransplante de células-tronco hematopoéticas em gamopatias monoclonais
Maiolino, Â., Solza, C., Barros, J. C., Coelho, É., Magalhães, R., Bittencourt, R., Atalla, Â., Carnevalli, E., Roithmann, S., & Hungria, V. (2010) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842010005000017
Allogeneic transplantation in multiple myeloma – How, when or at all?
Gahrton, G. (2015) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2015.03.005
“However, in the four studies that used TBI 2 Gy [29, 33, 34, 36] with or without fludarabine, the results”
BackgroundInfluentialLeukemias and plasma cell dyscrasias
Wiernik, P. H. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.07.002
THE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
Schots, R., Delforge, M., André, M. P. E., Bries, G., Caers, J., Demuynck, H., Prijck, B. D., Samblanx, H. D., Kentos, A., Meuleman, N., et al. (2010) · Acta Clinica Belgica · doi:10.1179/acb.2010.055
“In the Italian trial, alloSCT was superior, mostly due to a marked reduction in relapse rate (92).”
BackgroundTan, Y., Xu, S., Li, X., & Chen, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010484.pub2
I04 Stem cell transplantation in multiple myeloma
Gahrton, G. (2007) · Blood Reviews · doi:10.1016/s0268-960x(07)70005-x
Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma
Menzel, H., Hinmüller, K., Kolb, H., Schuster, T., Höllein, A., Peschel, C., Dechow, T. N., & Keller, U. B. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620711433317
“…patients with symptomatic MM under the age of 65 years without substantial organ dysfunction is induction therapy including one of the new substances followed by HD chemotherapy and autoSCT, or alloSCT in patients with an HLA-identical donor [Bruno et al. 2007; Kroger, 2010; Kumar et al. 2011].”
BackgroundMethodInfluentialAllogeneic Stem Cell Transplantation for Multiple Myeloma: Maxi, Mini, or in Between
Bensinger, W., Rotta, M., & Maloney, D. G. (2009) · Clinical Lymphoma & Myeloma · doi:10.1016/s1557-9190(11)70835-6
Self-citationAllogeneic transplantation in multiple myeloma
Birrell, G. W., Chen, P., Kozlov, S., & Scott, S. P. (2008)
New drugs in the treatment of chronic myeloid leukaemia
Cilloni, D., Rotolo, A., Nicoli, P., Bosa, M., & Saglio, G. N. (2008) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842008000800007
What is the correct philosophy for the treatment of multiple myeloma?
Gertz, M. A. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701704639
“’’ In the context of ongoing research, it remains appropriate to continue the search for a cure as has been demonstrated in recipients of allogeneic Tlymphocytes [8].”
BackgroundZver, A., Zver, S., Mlakar, U., Zupan, I. P., & Pretnar, J. (2008) · Slovenian Medical Journal
Does the reduced intensity conditioning regimen respect its promises?
Angarano, R., Donnini, I., & Bosi, A. (2013) · Drugs and Cell Therapies in Hematology · doi:10.4081/dcth.2013.53
Multiple Myeloma in a 50-Year-Old with an HLA-Identical Sibling
Koreth, J. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.08.042
Investigator, P., & Lokhorst, H. M. (2011)
Allogeneic Transplantation for the Treatment of Multiple Myeloma
Olin, R. L., Vogl, D. T., & Stadtmauer, E. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-478-0_16
“Bruno [92] 80 auto-allo TBI 10 43/64 Median 80 m*”
BackgroundInfluentialConcise of the Disease and Treatment Options
Durie, B. G. M. (2015)
The Role of Allogeneic Transplantation for Multiple Myeloma in Older Adults
Klepin, H. D., & Hurd, D. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-478-0_9
“A prospective study of 162 consecutive patients (median age 55; range 30–65 years) compared RIC allogeneic transplantation from a sibling donor with tandem autologous transplantation in newly diagnosed multiple myeloma [69].”
BackgroundReduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT)
Servais, S., Beguin, Y. P., & Baron, F. (2011) · ORBi (University of Liège)
Traitement du myélome multiple
Casassus, P. (2013) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(12)50916-7
Allogeneic transplantation for multiple myeloma: yes, no or maybe?
Bruno, B. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.12
Self-citationAllogeneic stem cell transplantation for multiple myeloma
Sunami, K. (2015) · Journal of Hematopoietic Cell Transplantation · doi:10.7889/hct.4.1
Mori, M., Kondo, T., Hishizawa, M., Nishikori, M., Yamashita, K., Ichinohe, T., Kadowaki, N., Ishikawa, T., & Takaori‐Kondo, A. (2013) · Journal of Hematopoietic Cell Transplantation · doi:10.7889/hct.2.25
The role of allogeneic stem cell transplantation in multiple myeloma in the new drug era
Kröger, N. M. (2013) · Drugs and Cell Therapies in Hematology · doi:10.4081/dcth.2013.41
Allogeneic vs. Second Autologous Stem-Cell Transplantation for Newly Diagnosed Myeloma
Williams, M. E. (2007) · Journal watch · doi:10.1056/oh200703140000001
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-4-379-414 · Cited by 7
Therapeutic decision making in hematopoietic SCT for multiple myeloma
Munker, R., Lazarus, H. M., & Atkinson, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139519205.012
Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma
Ballester, O. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511575525.011
Treatment of Multiple Myeloma Patients Who Have Received at Least One Prior Therapy
Harousseau, J. (2007) · European Oncology & Haematology · doi:10.17925/eoh.2007.0.2.32
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
Bensinger, W. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.009
Identifying responders to melphalan and dexamethasone for newly diagnosed multiple myeloma patients
Esmaeili, A. A. (2008) · QSpace (Queen's University Library)
Roos‐Weil, D., Moreau, P., Avet‐Loiseau, H., Kuentz, M., Milpied, N. J., Golmard, J. L., Socié, G., Fürst, S., Huynh, A., Vigouroux, S., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1187.1187
2014 TRANSPLANT REVIEW GUIDELINES
Organ, S. (2014)
Allogeneic hematopoietic transplant in multiple myeloma
Hari, P., & Dhakal, B. (2017) · Wiley eBooks · doi:10.1002/9781119095491.ch23
Allogeneic Hematopoietic Cell Transplants for Plasma Cell Myeloma
Giever, T. A., & Hari, P. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316335727.049
Plasma Cell Dyscrasias: Hematopoietic Cell Transplants
Abutalib, S. A. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316335727.047
VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Nakaseko, C. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.1246
RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms
Weisel, K. C., & Kanz, L. (2017) · Info Onkologie · doi:10.1007/s15004-017-5793-6
“Prospektive Studien, in denen der Stellenwert der allogenen Stammzelltransplantation für die erapie des MM evaluiert worden war, führten zu gegensätzlichen Ergebnissen: Daten aus drei „positiven“ Studien sprachen für den Einsatz der allogenen Stammzelltransplantation, Daten aus vier „negativen“ Studien dagegen [41, 4…”
RetractedRole of Hematopoietic Cell Transplantation for Myeloma
Landau, H. J., & Giralt, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_29
Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Chakraborty, R., & Gertz, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_28
Kapoor, P., & Martenson, J. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_19
Chen, A., Hoppe, R. T., & Coutre, S. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5897-7.00065-2
Miguel, J. F. S., & Bladé, J. (2010) · Wiley eBooks · doi:10.1002/9781444323160.ch31 · Cited by 1
Stem cell transplant and the potential role of CAR-T cells in multiple myeloma
Sabbagh, N., & Zander, A. R. (2018) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2018-7-4-8-15
Natural killer cells, multiple myeloma, and daratumumab : a love-hate relationship
Chrobok, M. (2019) · Figshare
Radiobiologic Factors to Consider with Total Marrow Irradiation
Hui, S. K., & Storme, G. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-38692-4_3
Hämatologische und onkologische Erkrankungen
Schrezenmeier, H., & Hiller, E. (2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50012-1
van Rhee, F., & Nair, B. P. (2009) · Elsevier eBooks · doi:10.1016/b978-0-443-10147-2.50012-6 · Cited by 1
Hämatologische und onkologische Erkrankungen
Gstatter, S., & Berthold, H. K. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-45381-6.00039-6
Nanotherapeutic platforms for osteoarticular tuberculosis
Osmani, R. A. M., Singh, E., Bhosale, R. R., Vaghela, R., & Patravale, V. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819985-5.00006-1
The Landscape of Checkpoint Inhibition in the Management of Hematological Malignancies
Arslan, S., Herrera, A. F., & Malki, M. M. A. (2021) · Cancer Research Journal · doi:10.11648/j.crj.20210902.16
“[29, 30] AutoHCT provides PFS and OS benefit, but most of the patients still relapse likely secondary to T-cell exhaustion [31].”
BackgroundDunne, T. (2022) · Memorial University Research Repository (Memorial University) · doi:10.48336/fkmp-4k25
Bone remodeling: analysis, discussion, and perspectives
Kahla, R. B., & Barkaoui, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88467-9.00007-2
Multiple Myeloma Surveillance Counterpoint: Australia
Khoo, L., & Joshua, D. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-969-7_100
Bianchi, G., & Anderson, K. C. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch33
Current Awareness in Hematological Oncology
(2007) · Hematological Oncology · doi:10.1002/hon.798
Hematopoietic Cell Transplantation for Multiple Myeloma
Krishnan, A. Y., & Giralt, S. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch55
HLA-matched donor HSC allografts improve survival in newly diagnosed myeloma
(2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0835
Paraproteinämien / Multiples Myelom
Holzer, S., & Drach, J. W. (2008) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-008-0040-6
Bladé, J., Bruno, B., & Mohty, M. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_80
Self-citation(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00022-4
Merz, A. M. A., Merz, M., Hillengaß, J., Holstein, S. A., & McCarthy, P. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_18
Multiple Myeloma and Plasmacytoma
Chng, W. J., & Lu, J. J. (2008) · Medical radiology · doi:10.1007/978-3-540-77385-6_29
Tan, Y. H., Xu, S., Li, X., & Chen, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010484
RetractedAtanazio, M. J. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-15062022-092534
de Charry, F., Konopacki, J., Bugier, S., Foissaud, V., Sloma, I., Malfuson, J., & Arnautou, P. (2023) · Leukemia Research Reports · doi:10.1016/j.lrr.2023.100366
Hematopoietic Cell Transplantation in Multiple Myeloma
Ghanem, S., & Qazilbash, M. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00021-8
Bispecific T Cell Engager and Cell Based Immune Therapy in Multiple Myeloma
Mohan, M., and, P. H., & Chhabra, S. (2023) · Wiley eBooks · doi:10.1002/9781119823193.ch57
Biglari, M., & Shiraji, S. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00118-9
Allogeneic Hematopoietic Stem Cell Transplant
Batgi, H., Bozan, E., Yaman, S., & Başçı, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00136-0
Mackowski, N. (2023) · theses.fr (ABES) · doi:10.70675/709bc965zd886z4e26z8239z5d321d206ce9
LeBlanc, R., Thiant, S., Terra, R., Ahmad, I., Claveau, J., Bambace, N. M., Bernard, L., Cohen, S., Delisle, J., Lachance, S., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110535
A multi-institutional survey on technical variations in total body irradiation in Japan
Kitagawa, M., Notake, R., Nakahara, R., Hatanaka, S., Saho, T., & Matsuda, K. (2025) · Radiological Physics and Technology · doi:10.1007/s12194-025-00894-2
“It is essential to irradiate the entire body using a homogeneous radiation dose during TBI [39].”
Allogenic Hematopoietic Cell Transplant in Hematological Malignancies: Controversies and Perspective
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6196-6
Costello, C. L., & Fonseca, R. (2022) · doi:10.1182/ashsap8.chapter25
Current Status of BoneMarrow Transplantation for Treatment of Cancer
Ball, E. D., Bashey, A., Carrier, E., Castro, J. E., Holman, P., & Lane, T. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9704-0_23
“A similar study from an Italian consortium showed superiority in the allogeneic HSCT arm of the study compared to tandem autologous stem cell transplantation [28].”
ResultMultiples Myelom und verwandte Plasmazellerkrankungen
Sezer, O. (2007) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50037-6
Metadata
- Authors
- Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G., & Boccadoro, M.
- Affiliations
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Udine (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- Candiolo Cancer Institute (IT)
- University of Washington (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-03-15
- Volume
- 356
- Issue
- 11
- Pages
- 1110-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010766702
- Semantic Scholar
- 67383c7f6bdb3318b2667d1aad826b28d4117193
- Cited by
- 501
- References
- 35
- Citations by year
- 2025: 3 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 13 · 2018: 16 · 2017: 26 · 2016: 22 · 2015: 34 · 2014: 23 · 2013: 43 · 2012: 33
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Cancer Institute (CA 78902, P01CA078902)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, allogeneic stem cell transplantation, autologous stem cell transplantation, matched sibling donor, graft-versus-host disease, overall survival, event-free survival, complete remission, non-relapse mortality, newly diagnosed multiple myeloma
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Graft vs Host Disease, Histocompatibility Testing, Humans, Male, Middle Aged, Multiple Myeloma, Transplantation, Autologous, Transplantation, Homologous, Multivariate Analysis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Siblings
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.